Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
- Uchealth University of Colorado Hospital
Aurora, Colorado, United States
- Moffitt Cancer Center
Tampa, Florida, United States
- Moffitt Cancer Center-International Plaza
Tampa, Florida, United States
- Emory University Hospital/winship Cancer Institute
Atlanta, Georgia, United States
- University of Kentucky/markey Cancer Center
Lexington, Kentucky, United States
- Johns Hopkins University/sidney Kimmel Cancer Center
Baltimore, Maryland, United States
- Brigham and Women'S Hospital
Boston, Massachusetts, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
- Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
New Brunswick, New Jersey, United States
- Unc Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
- Duke University Medical Center
Durham, North Carolina, United States
- Duke Raleigh Hospital
Raleigh, North Carolina, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
- University of Pittsburgh Cancer Institute (upci)
Pittsburgh, Pennsylvania, United States
- University of Virginia Cancer Center
Charlottesville, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Aug 2016
- Primary completion
- 26 Oct 2022
- Completion
- 4 Dec 2023
- Last update posted
- 21 Aug 2024
- Registered enrollment
- 27
- Registry id
- NCT02520778
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.